scispace - formally typeset
H

Hongling Li

Researcher at Peking Union Medical College

Publications -  28
Citations -  1800

Hongling Li is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Mesenchymal stem cell & Adipogenesis. The author has an hindex of 17, co-authored 26 publications receiving 1496 citations. Previous affiliations of Hongling Li include Peking Union Medical College Hospital.

Papers
More filters
Journal ArticleDOI

Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression.

TL;DR: The results suggested that miR-22 acted as a critical regulator of balance between adipogenic and osteogenic differentiation of hADMSCs by repressing its target HDAC6.
Journal ArticleDOI

miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1

TL;DR: The findings suggest that miR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/β-catenin.
Journal ArticleDOI

Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway

TL;DR: A novel mechanism by which lung tumor cell-derived exosomes induce pro-inflammatory activity of MSCs which in turn get tumor supportive characteristics is suggested.
Journal ArticleDOI

MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2

TL;DR: Findings imply that miR‐100 plays a negative role in osteogenic differentiation and might act through targeting BMPR2, similar to the effect of upregulation miR-100.
Journal ArticleDOI

miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells

TL;DR: MiR-17-5p and miR-106a regulate osteogenic and adipogenic lineage commitment of hADSCs by directly targeting BMP2, and subsequently decreased osteogenic TAZ, MSX2 and Runx 2, and increased adipogenic C/EBPα and PPARγ.